oxonic acid has been researched along with Ductal Carcinoma in 6 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with resected pancreatic cancer were randomly assigned (in a 1:1 ratio) to receive gemcitabine (1000 mg/m(2), intravenously administered on days 1, 8, and 15, every 4 weeks [one cycle], for up to six cycles) or S-1 (40 mg, 50 mg, or 60 mg according to body-surface area, orally administered twice a day for 28 days followed by a 14 day rest, every 6 weeks [one cycle], for up to four cycles) at the data centre by a modified minimisation method, balancing residual tumour status, nodal status, and institutions." | 2.82 | Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). ( Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R, 2016) |
| "Locally advanced breast cancer sometimes results in a large chest wall defect at mastectomy." | 1.62 | Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer. ( Fukuma, E; Haruyama, Y; Koshida, Y; Nakagawa, M; Nashimoto, M; Sakamoto, N, 2021) |
| "The diagnosis was made as right breast cancer (T4c, N3c, M1, and stage IV)." | 1.35 | [A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies]. ( Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sakamoto, N | 1 |
| Nashimoto, M | 1 |
| Nakagawa, M | 1 |
| Haruyama, Y | 1 |
| Koshida, Y | 1 |
| Fukuma, E | 1 |
| Ko, AH | 1 |
| Uesaka, K | 2 |
| Boku, N | 2 |
| Fukutomi, A | 2 |
| Okamura, Y | 1 |
| Konishi, M | 1 |
| Matsumoto, I | 1 |
| Kaneoka, Y | 1 |
| Shimizu, Y | 1 |
| Nakamori, S | 1 |
| Sakamoto, H | 1 |
| Morinaga, S | 1 |
| Kainuma, O | 1 |
| Imai, K | 1 |
| Sata, N | 1 |
| Hishinuma, S | 1 |
| Ojima, H | 1 |
| Yamaguchi, R | 1 |
| Hirano, S | 1 |
| Sudo, T | 1 |
| Ohashi, Y | 1 |
| Matsumura, T | 1 |
| Ohzato, H | 1 |
| Yamamoto, T | 1 |
| Ota, K | 1 |
| Mabuchi, E | 1 |
| Miwa, H | 1 |
| Ikeda, H | 1 |
| Fukunaga, M | 1 |
| Furukawa, H | 1 |
| Aoyagi, H | 1 |
| Kaneko, J | 1 |
| Makinose, T | 1 |
| Someno, Y | 1 |
| Katsuta, E | 1 |
| Saguchi, M | 1 |
| Okubo, K | 1 |
| Hamada, S | 1 |
| Sekine, T | 1 |
| Sato, T | 1 |
| Sugihara, K | 1 |
| Maejima, S | 1 |
| Maeda, A | 1 |
| Kondo, S | 1 |
| Kinoshita, T | 1 |
| Nagino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150] | Phase 2/Phase 3 | 231 participants (Anticipated) | Interventional | 2020-01-05 | Recruiting | ||
| Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study[NCT04737551] | 400 participants (Anticipated) | Observational [Patient Registry] | 2020-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxonic acid and Ductal Carcinoma
| Article | Year |
|---|---|
[A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Deox | 2009 |
2 trials available for oxonic acid and Ductal Carcinoma
| Article | Year |
|---|---|
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality | 2016 |
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuv | 2008 |
3 other studies available for oxonic acid and Ductal Carcinoma
| Article | Year |
|---|---|
Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Axilla; Bi | 2021 |
Raising the bar for the adjuvant treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Ductal; Deoxycytidine; Female; Humans; Male; Oxonic Acid | 2016 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2009 |